Processing math: 100%
Research article

Stationary distribution and extinction of a stochastic Alzheimer's disease model

  • Received: 16 May 2023 Revised: 17 July 2023 Accepted: 18 July 2023 Published: 24 July 2023
  • MSC : 60G10, 34F05, 92B05

  • In this paper, a stochastic Alzheimer's disease model with the effect of calcium on amyloid beta is proposed. The Lyapunov function is constructed, followed by the feasibility and positivity and the existence of a stationary distribution for the positive solutions of the proposed model. The sufficient conditions for the extinction of the stochastic Alzheimer's disease model are derived through the Lyapunov function. This indicates that beta-amyloid plaque and the complex of beta-amyloid oligomers with prion protein may go extinct and there is a possibility of a cure for the disease. Furthermore, our numerical simulations show that as the intensity of the random disturbance increases, the time it takes for the disease to go extinct decreases.

    Citation: Ruoyun Lang, Yuanshun Tan, Yu Mu. Stationary distribution and extinction of a stochastic Alzheimer's disease model[J]. AIMS Mathematics, 2023, 8(10): 23313-23335. doi: 10.3934/math.20231185

    Related Papers:

    [1] Xiaodong Wang, Kai Wang, Zhidong Teng . Global dynamics and density function in a class of stochastic SVI epidemic models with Lévy jumps and nonlinear incidence. AIMS Mathematics, 2023, 8(2): 2829-2855. doi: 10.3934/math.2023148
    [2] Yue Wu, Shenglong Chen, Ge Zhang, Zhiming Li . Dynamic analysis of a stochastic vector-borne model with direct transmission and media coverage. AIMS Mathematics, 2024, 9(4): 9128-9151. doi: 10.3934/math.2024444
    [3] Jinji Du, Chuangliang Qin, Yuanxian Hui . Optimal control and analysis of a stochastic SEIR epidemic model with nonlinear incidence and treatment. AIMS Mathematics, 2024, 9(12): 33532-33550. doi: 10.3934/math.20241600
    [4] Tingting Wang, Shulin Sun . Dynamics of a stochastic epidemic model with quarantine and non-monotone incidence. AIMS Mathematics, 2023, 8(6): 13241-13256. doi: 10.3934/math.2023669
    [5] Ying He, Bo Bi . Conditions for extinction and ergodicity of a stochastic Mycobacterium tuberculosis model with Markov switching. AIMS Mathematics, 2024, 9(11): 30686-30709. doi: 10.3934/math.20241482
    [6] Xiangming Zhao, Jianping Shi . Dynamic behavior of a stochastic SIR model with nonlinear incidence and recovery rates. AIMS Mathematics, 2023, 8(10): 25037-25059. doi: 10.3934/math.20231278
    [7] Yuhuai Zhang, Xinsheng Ma, Anwarud Din . Stationary distribution and extinction of a stochastic SEIQ epidemic model with a general incidence function and temporary immunity. AIMS Mathematics, 2021, 6(11): 12359-12378. doi: 10.3934/math.2021715
    [8] Yue Dong, Xinzhu Meng . Stochastic dynamic analysis of a chemostat model of intestinal microbes with migratory effect. AIMS Mathematics, 2023, 8(3): 6356-6374. doi: 10.3934/math.2023321
    [9] Ruyue Hu, Chi Han, Yifan Wu, Xiaohui Ai . Analysis of a stochastic Leslie-Gower three-species food chain system with Holling-II functional response and Ornstein-Uhlenbeck process. AIMS Mathematics, 2024, 9(7): 18910-18928. doi: 10.3934/math.2024920
    [10] Yan Ren, Yan Cheng, Yuzhen Chai, Ping Guo . Dynamics and density function of a HTLV-1 model with latent infection and Ornstein-Uhlenbeck process. AIMS Mathematics, 2024, 9(12): 36444-36469. doi: 10.3934/math.20241728
  • In this paper, a stochastic Alzheimer's disease model with the effect of calcium on amyloid beta is proposed. The Lyapunov function is constructed, followed by the feasibility and positivity and the existence of a stationary distribution for the positive solutions of the proposed model. The sufficient conditions for the extinction of the stochastic Alzheimer's disease model are derived through the Lyapunov function. This indicates that beta-amyloid plaque and the complex of beta-amyloid oligomers with prion protein may go extinct and there is a possibility of a cure for the disease. Furthermore, our numerical simulations show that as the intensity of the random disturbance increases, the time it takes for the disease to go extinct decreases.



    Alzheimer's disease (AD), a major form of dementia, is accompanied by cognitive decline, memory impairment, impaired ability to learn new information and language dysfunction. As one of the top 10 causes of death worldwide today, it will severely affect the daily life of the patient [1]. According to the global burden of disease study in 2019 (GBD 2019), the number of people with Alzheimer's-like dementia has 50 million in 2018 and it will reach 152 million by 2050 [2]. In the USA, total payments for medicare, long-term care, and hospice services for dementia are estimated to be up to fanxiexian_myfh335 billion in 2021 [3]. With no reliable and effective treatment, dementia will affect the patient's ability to perform daily live by impairing cognitive function and pose an increasing challenge to health care systems worldwide [4,5,6].

    In the earliest phase of Alzheimer's disease (cellular phase), amoid beta (Aβ) accumulate in the brain, along with the spread of tau pathology [7]. The peptide Aβ, obtained by amyloid precursor protein (APP), can form Aβ oligomers (two main Aβ forms, Aβ40 and Aβ42), which will reduce the number of synapses and decrease glucose metabolism in the brain. This process will finally lead to brain atrophy [8]. To discuss how Aβ peptide aggregates into Aβ oligomers, Masoud Hoore et al. [9] developed a model of Aβ fibrillation on a minimal scale. The results showed that Aβ monomers rapidly increased once Aβ oligomers produced. Furthermore, by considered Aβ40 and Aβ42 as two forms of Aβ oligomers, Li and Zhao [10] proved that the targeted therapeutic drug Aducanumab of Aβ cannot completely cure AD. However, many studies have found that the prion protein (PrPC) inhibits the activity of the protease that cleaves APP and slows the proliferation of Aβ [11,12]. To understand the dynamics of PrPC, Helal et al. [13] devised an in vitro model to study the role of protein and analyzed the kinetics of Aβ plaques, Aβ oligomers, PrPC and AβxPrPC complex. Considering the process of diffusion of these substances, Hu et al. [14] focused on the dynamic behaviors of the system in a finite time interval and under what conditions the state value may exceed a certain value.

    Various factors are involved in the transmission of neural signals. For example, in the cerebrospinal fluid, the level of Aβ oligomers is affected by Ca2+, microglia activity, reactive oxygen species and Na+ concentration etc. [15,16,17,18]. For example, Caluwé and Dupont [19] designed a positive loop between Aβ and Ca2+ to explore the role of Ca2+ on Aβ oligomers during the progression of a healthy pathological state to a severe pathology. All the factors always fluctuate in a small range over long periods which will affect the level of Aβ oligomers and the pathological status of AD. Therefore, stochastic perturbations cannot be ignored and parameters are often assumed in biomathematics to be perturbed by linear functions of white noise, a phenomenon described by stochastic differential equations (SDE) [20,21,22,23]. Hu et al. [24] formulated a stochastic model of the in vivo progression of AD incorporating the role of prions derived from Helal et al. [13] and discussed the existence of the ergodic stationary distribution of the model.

    Studies have been done on minimizing the concentrations of Aβ plaques and AβxPrPC complex in Alzheimer's disease models, but the conditions are complex and not well measured in many practical situations [14]. And the random factors in the interstitial fluid (ISF) cannot be neglected, therefore it is necessary to study stochastic models of Alzheimer's disease to explore the convergence to extinction in a probabilistic sense. For this purpose, we introduce calcium ions into the system based on Helal et al. [12] and consider the effect of random noise on Brownian motion in the environment. The main contributions of this paper are as follows:

    (ⅰ) A stochastic Alzheimer's disease model is formulated by taking the influence of calcium ions and environmental noise on Aβ oligomers into account.

    (ⅱ) The sufficient conditions for extinction of the model are established.

    The remaining paper is organized as follows. In the next section, the mathematical model of Alzheimer's disease with Ca2+ is established. Section 3 shows the existence, uniqueness and boundedness of the solution of the model. The conditions for the existence of a steady state distribution are derived in Section 4. Section 5 focuses on the threshold conditions for the extinction of plaques and complex and shows how random noise affects the development of Alzheimer's disease. In Section 6, a numerical simulation is performed to prove the validity of the theoretical derivation. In the ending section, we present our conclusion.

    In this section, we introduce the model and then give the necessary definitions and lemmas.

    To explore the role of prions in memory impairment, Helal et al. [13] introduced a mathematical model of in vivo Alzheimer's disease progression that explains the relationship between Aβ plaque, Aβ oligomers, PrPC and AβxPrPC complex. The model is as follows

    {˙A=αunηA,˙u=λ2τup+σbαnunρuAk2u,˙p=λ3τup+σbk3p,˙b=τupσbk4b. (2.1)

    Where A(t),u(t),p(t) and b(t) represent the concentration of Aβ plaque, Aβ oligomers, PrPC and AβxPrPC complex. Where α is the rate of formation of oligomers, η is the rate of degradation of a plaque, τ is the rate of binding of Aβ oligomers to PrPC, σ is the rate of unbinding of AβxPrPC, ρ is the conversion rate of oligomers to plaque, ki(i=2,3,4) is the degradation of Aβ oligomers, PrPC and AβxPrPC complex, λi(i=2,3) is the source of PrPC and Aβ oligomers.

    In this paper, by considering that the presence of PrPC can optimize and control Ca2+ input [11] and this process is affected by the level of Ca2+, it can be assumed to be a bilinear model [25,26]. Furthermore, there is positive feedback between the level of Ca2+ and the level of Aβ [19], so Ca2+ is introduced into the model. Moreover, due to the randomness of real life, especially in the neurobiological environment, there exist various random factors involved in signaling. In many stochastic models of infectious diseases, factors such as noise, Brownian motion, pollution, etc. have been considered [27,28,29]. Then, we assume that the white noise in the environment is proportional to the variables C(t), u(t), p(t), b(t), and A(t). The stochastic differential model can be written as

    {dC=(λ1+v2uv3pCk1C)dt+ξ1CdB1(t),du=(λ2τup+σb+v1Ck+CαnunρuAk2u)dt+ξ2udB2(t),dp=(λ3τup+σbk3p)dt+ξ3pdB3(t),db=(τupσbk4b)dt+ξ4bdB4(t),dA=(αunηA)dt+ξ5AdB5(t). (2.2)

    Where λ1 is the source of Ca2+, v2 is the acceleration of Ca2+ due to Aβ, v3 is the limitation of Ca2+ due to PrPC, k1 is the degradation of Ca2+, v1is the maximal rate of the positive feedback of Ca2+ on Aβ and k is half-saturation constant, Bi(t) denote independent and standard Brownian motions and ξ2i are the intensities of the white noise, i=1,2,3,4,5. The other parameters in model (2.2) have identical significance as in model (2.1). Our main purpose is to explore the threshold related to epidemic transmission and try to establish the threshold dynamics of model (2.2).

    Throughout this paper, we let (Ω,F,{F}l0,P) be a complete probability space with filtration {F}l0 satisfying the usual conditions (that is to say, it is increasing and right continuous while F0 contains all P -null sets). Let Bi(t)(i=1,2,3...) denote the independent standard Brownian motions defined on this probability space. We also denote Rd+={xRd:xi>0 for all 1id} and ab=min{a,b}.

    Generally speaking, consider the d-dimensional stochastic differential equation (SDE)

    dx(t)=f(x(t),t)dt+g(x(t),t)dBt, (2.3)

    where f(t,x(t)) is a function in Rd defined in [t0,]×Rd and g(x(t),t) is a d×m matrix, f, g are locally Lipschitz functions in x. Bt denotes an m-dimensional standard Brownian motion (Bt=(B1(t),B2(t),...,Bm(t))T, Bi(t)(i=1,2,...,m) is standard normal distribution and Bi(t)N(0,t)) defined on the complete probability space (Ω,F,{F}t0,P). Denote by C2,1(Rd×[t0,];R+) the family of all nonnegative functions V(x(t),t) defined on Rd×[t0,] such that they are continuously twice differentiable in x and once in t.

    We define the differential operator L of Eq (2.3) by [30]

    L=t+di=1fi(x,t)xi+12di,j=1[gT(x,t)g(x,t)]ij2xixj. (2.4)

    If L acts on a function VC2,1(Rd×[t0,],R+) then

    LV(x,t)=Vt(x,t)+Vx(x,t)f(x,t)+12trace[gT(x,t)Vxx(x,t)g(x,t)] (2.5)

    where Vt(x,t)=Vt, Vx(x,t)=(Vxi,,Vxd),Vxx(x,t)=(2Vxixj)d×d. From Itô's formula, if x(t)Rd, then

    dV(x,t)=LV(x,t)dt+Vx(x,t)g(x,t)dBt. (2.6)

    Here are some definitions and lemmas what we will use in the following text.

    Definition 1. [21] (Fokker-Plank equation) The respective Fokker-Plank equation for an unknown probability density function (PDF) in variables x(t) can be assigned to Eq (2.3):

    tp(t,x)=x(fp(t,x))+2x2(12g2p(t,x)),

    where p(t,x) means the probability density function of x(t) at t.

    Definition 2. [30] For a set Ωk composed of elementary random events ω, the indicator function of Ωk, denoted by 1Ωk, is the random variable, where

    1Ωk={1ifωΩk,0ifωΩk.

    Definition 3. [31] The SDE (2.3) is said to be stochastically ultimately bounded if for any ε(0,1), there is a positive constant χ=χ(ε) such that for any initial data {x(t):τt0}C([τ,0];Rd+), the solution x(t) of Eq (2.3) has the property that

    lim suptP{|x(t)|>χ}<ε. (2.7)

    Definition 4. [30] For the Markov process {X(t),t0}, the state space is S={1,2,...,T}, if there exists a positive integer m such that

    pij(m)>0foreveryi,jS,

    then X(t) has the ergodic feature.

    Definition 5. [23,24,27] The diffusion matrix of system (2.3) is defined as follows:

    A(x)=(ai,j(x)),ai,j(x)=kr=1gir(x).gjr(x).

    Definition 6. [23] Let N(t)=(Ni(t))T(i=1,2,...,d) be the solution of model (2.2) with initial value N(0)Rd+. If for any 0<ε<1, there exists a pair of positive constants θ=θ(ε) and χ=χ(ε) such that

    limtinfP{Ni(t)θ}1ε,limtinfP{Ni(t)χ}1ε

    then the species i is said to be stochastically permanent.

    Definition 7. [20,22,28] For model (2.3), the infected individuals xi(t) are said to be extinctive if limtxi(t)=0, almost surely (a.s.).

    Lemma 1. [23] (Chebychev inequality) Let X={Xt}t0 be a nonnegative random variable, its mean value is noted as E(X), for a given r>0. Then,

    P(Xr)1rE(X)foreveryr>0.

    Lemma 2. [21,28] The Markov process X(t) has a unique ergodic stationary distribution μ() if there exists a bound DRd with regular boundary Γ and the following conditions:

    (1) In the domain D and some neighborhood thereof, the smallest eigenvalue of the diffusion matrix A(x) is bounded away from zero.

    (2) There exists a nonnegative C2-function V such that LV is negative for any RdD. Then,

    Px{limT+1TT0f(X(t))dt=Edf(x)μ(dx)}=1

    for all xRd, where f is a function integrable with respect to the measure μ.

    Lemma 3. [20] (Strong Law of Large Number) Let M={M}t0 be continuous and real-valued local martingale, which vanishes as t0, then

    limtM,Mt=,a.s.,limtMtM,Mt=0,a.s.limtsupM,Mtt<0,a.s.,limtMtt=0,a.s.

    Theorem 1. For any initial value

    X(0)=(C(0),u(0),p(0),b(0),A(0))R5+,

    there exists a positive salutation X(t)=(C(t),u(t),p(t),b(t),A(t)) of the stochastic model (2.2) for t0 and the solution will hold in R5+ with probability one.

    Proof. We can easily know that the coefficients of model (2.2) are locally Lipschitz continuous. Then, for any given initial value (C(0),u(0),p(0),b(0),A(0))R5+, there exists a unique local solution (C(0),u(0),p(0),b(0),A(0)) on t[0,τe), where τe is the explosion time (see [20]). To prove that the solution is global, all you have to do is to prove τe= almost surely. Let k00 be sufficiently large so that (C(0),u(0),p(0),b(0),A(0)) all lie within the interval [1k0,k0]. For each integer kk0, define the following stopping time:

    τk=inf{t[0,τe):min{(C(0),u(0),p(0),b(0),A(0))}1k or max{(C(0),u(0),p(0),b(0),A(0))k}}.

    Where throughout this paper, we setinf= (as usual denotes the empty set). According to the definition of the stopping time, τk is increasing as k. Set τ=limtτk with ττe almost surely. Namely, we need to show that τ= almost surely. If τ, we assumed that there exists a pair of constants T>0 and ϵ(0,1) such that

    P{τT}>ϵ. (3.1)

    As a result, there is an integer k1k0 such that

    P{τkT}>ϵ, for all kk1.

    Now, we define a C5-function V(C,u,p,b,A)R5+ as follows

    V(C,u,p,b,A)=m1(A1lnA)+C1lnC+m2u1lnu+m3P1lnP+m4(b1lnb),

    where mi(i=1,2,3,4) are positive constants to be determined below. Then, by using the Itô's formula, we have

    dV=LVdt+m1(A1)ξ5dB5(t)+(C1)ξ1dB1(t)+(m2u1)ξ2dB2(t)+(m3p1)ξ3dB3(t)+m4(b1)ξ4dB4(t),

    where

    LV=m1(11A)(αunηA)+m1ξ252+(11C)(λ1+v2u+v3pCk1C)+ξ212+(m21U)(λ2τup+σb+v1Ck+CαnunρuAk2u)+ξ222+(m31p)(λ3τup+σbk3p)+ξ232+m4(11b)(τupσbk4b)+m4ξ242=m1αunm1ηA+m1ηm1Aαun+m1ξ252+λ1+v2u+v3pCk1C+k1v3p1C(λ1+v2u)+ξ212+m2λ2m2(τupσb)+m2v1Ck+Cm2αnunm2ρuAm2k2u+τp+αnun1+ρA+k21u(λ2+σb+v1Ck+C)+ξ222+m3λ3m3(τupσb)m3k3p+τu+k31p(λ3+σb)+ξ232+m4(τupσb)m4k4b+m4(σ+k4)m4bτup+m4ξ242(m2nm1)αun+αnun1+(v2m2k2+τ)u(m1ηρ)A+(τm3k3)p+m1η+m3ξ252+λ1+k1+ξ212+m2λ2+m2v1+k2+ξ222+m3λ3+k3+ξ232+m4(σ+k4)+m4ξ242+(m4m2m3)(τupσb).

    Choosing

    m1=ρη,m2=max{v2+τk2+1,m1n+1},
    m3=τk3+1,m4=m3+m2,

    such that

    v2m2k2+τ<0,m2nm1>0,τm3k3<0.

    And there exists a constant K such that LVK, where K is define as follows

    K:=max{(m2nm1)αun+αnun1+m1η+m3ξ252+λ1+k1+ξ212+m2λ2+m2v1+k2+ξ222+m3λ3+k3+ξ232+m4(σ+k4)+m4ξ242}.

    Integration of the above inequality from 0 to τkT and taking the expectation on both sides, we get the following inequality

    E(V(C(τkT),u(τkT),p(τkT),b(τkT),A(τkT)))V(C(0),u(0),p(0),b(0),A(0))+TK. (3.2)

    Now, we set Ωk={τkT}, kk1. It follows from the inequality (3.1) that P(Ωk)ε. Note that for each ωΩk, C(τk,ω), u(τk,ω), p(τk,ω), b(τk,ω), A(τk,ω) equals either k or 1k. Consequently,

    V(V(C(τkT),u(τkT),p(τkT),b(τkT),A(τkT)))min{k1lnk,1k1+lnk}. (3.3)

    From (3.2) and (3.3) we get

    V(C(0),u(0),p(0),b(0),A(0))+TKE(1Ωk(ω)V(C(τk,ω),u(τk,ω),p(τk,ω),b(τk,ω),A(τk,ω)))εmin{k1lnk,1k1+lnk},

    where 1Ωk is the indicator function of Ωk. Letting k leads to

    >V(C(0),u(0),p(0),b(0),A(0))+TK=.

    This is a contradiction. As a consequence, τ= a.s. The proof is completed.

    Theorem 2. For any initial value X(0)=(C(0),u(0),p(0),b(0),A(0))R5+, the solutions of the model (2.2) are stochastically ultimately bounded and permanent.

    Proof. For facilitate calculation, define N=nA+mC+u+p+2b, choosing Λ=min{η,k1,k2mv2,k3+mv3,k4}, 0<m<min{k2v2,k3v3} and define

    V=1N+N.

    By using the Itô's formula, we have

    LV=mλ1+λ2+λ3ηnA+mv2umv3pmk1C+v1Ck+CρuAk2uk3p2k4b1N2(mλ1+λ2+λ3ηnA+mv2umv3pmk1c+v1Ck+CρuA)+1N2(k2uk3p+2k4b)+1N3(ξ25n2A2+ξ21m2C2+ξ22u2+ξ23p2+4ξ24b2)mλ1+λ2+λ3+v1ηnAmk1C(k2mv2)u(k3+mv3)p2k4b1N2(mλ1+λ2+λ3+v1)1N2(ηnAmk1C(k2mv3)u)+1N2((k3mv3)p+2k4b)+1N3(ξ25n2A2+ξ21m2C2+ξ22u2+ξ23p2+4ξ24b2)mλ1+λ2+λ3+v1Λ(nA+mC+u+p+2b)1N2(mλ1+λ2+λ3+v1)+1N2(ηnAmk1C(k2mv3)u(k3mv3)p2k4b)+1N(Λ+ξ25+ξ21+ξ22+ξ23+ξ24)GΛV,

    where

    G=4(mλ1+λ2+λ3+v1)2+(Λ+ξ25+ξ21+ξ22+ξ23+ξ24)24(mλ1+λ2+λ3+v1).

    Then, by a similar proof of Theorem 4.3 in literature [32] we can get the X(t) of model (2.2) is V-geometrically ergodic. And through a simple calculation we have

    E[eΛtV]=E[V(0)]+E[t0eΛs(ΛV(s)+LV(s))ds]E[V(0)]+GE[t0eΛsds]=E[V(0)]+GΛ(eΛt1).

    It follows that

    E[V(t)]eΛtE[V(0)]+GΛ(1eΛt)E[V(0)]+GΛ:=H.

    Thus, limtsupE[V(t)]H, we chose a constant χ which is sufficiently large, such that Hχ<1. By using Chebychev inequality in Lemma {1},

    P{V(t)>χ}1χE[V(t)]Hχ:=ε.

    Note that,

    1εP{V(t)χ}P{1χNχ}.

    That means,

    P{N>χ}+P{N<1χ}<ε.

    Thus,

    P{A(t),C(t),u(t),p(t),b(t)∣>χ}P{N>χ}<ε.

    According to Definition 3 and Definition 6, model (2.2) is stochastically ultimately bounded and permanent. The proof is completed.

    In this section, we will consider whether there is a unique stationary distribution of the model (2.2) that allows the disease to persist rather than die off.

    Theorem 3. If there exist constants ci(i=1,2,3) such that inequality (4.1) holds then for any initial value

    X(0)=(C(0),u(0),p(0),b(0),A(0))R5+,

    the model (2.2) admits a unique stationary distribution μ() and it has the ergodic feature.

    {c1ηnρ>0,c2k2v2τ>0,c3k3τ>0,c2c1>0. (4.1)

    Proof. According to Lemma 5, the diffusion matrix of model (2.2) is given by

    a(x)=[ξ21C200000ξ22u200000ξ23p200000ξ24b200000ξ25A2].

    Choose

    G=min(C,u,p,b,A)DδR4+{ξ21C2,ξ22u2,ξ23p2,ξ24b2,ξ21A2},

    we can get that

    4i,j=1aij(C,u,p,b,A)θiθj=ξ21C2θ22+ξ22u2θ22+ξ23p2θ23+ξ24b2θ24+ξ25A2θ25Gθ2,

    for any (C,u,p,b,A)D,θ=(θ1,θ2,θ3,θ4,θ5)R5+. Then the condition (1) in Lemma 2 is satisfied.

    To prove condition (2) of Lemma 2 is fulfilled, we need to develop a non-negative C5function V: R5+R. To do this, we first define

    V1(C,u,p,b,A)=c1nA+C+c2u+c3p+(c2+c3)b.

    By using the Itô's formula in the proposed model (2.2), we obtain

    L(lnC)=λ1Cv2uCv3PC+k1+ξ212,L(lnu)=λ2u+k2+τpσbuv1C(k+C)u+αnun1+ρA+ξ222,L(lnp)=λ3p+k3+τuσbp+ξ232,L(lnb)=τupb+σ+δ+ξ242,L(lnnA)=αunA+η+n2ξ252.

    Therefore, we have

    LV1=L(c1nA+C+c2u+c3p+(c2+c3)b)=c1αnunc1ηnA+λ1+v2uv3pCk1C+c2λ2+c2v1Ck+Cc2αnunc2ρuAc2k2uc3k3p(c2+c3)k4b(c2c1)αnunc1ηnAk1C(c2k2v2)uc3k3p(c2+c3)k4b+λ1+c2λ2+c2v1.

    Let

    V2(C,u,p,b,A)=V1lnnAlnClnulnplnb.

    In addition, we can obtain

    LV2=LV1αunA+η+n2ξ252λ1Cv2uCv3PC+k1+ξ212λ2u+k2+τpσbuv1C(k+C)u+αnun1+ρA+ξ222λ3p+k3+τuσbp+ξ232τupb+σ+δ+ξ242(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb(c2c1)αnun+αnun1+λ1+c2λ2+c2v1+η+k1+k2+k3+σ+δ+n2ξ252+ξ212+ξ222+ξ232+ξ242.

    For the sake of simplicity, we define

    F=max{(c2c1)αnun+αnun1+λ1+c2λ2+c2v1+η+k1+k2+k3+σ+δ+n2ξ252+ξ212+ξ222+ξ232+ξ242}.

    Also,

    M=max{F,v2+v3,σ}.

    Now we define a C5-function V(C,u,p,b,A)R5+ as follows

    V(C,u,p,b,A)=V2(C,u,p,b,A)V2(C0,u0,p0,b0,A0).

    Applying the Itô's formula and using the proposed model, we get

    LV(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M.

    The next step is to define the set

    D={εC1ε,εu1ε,εp1ε,ε3b1ε3,εn+1A1εn+1},

    where 0<ϵ<1 is a constant that is sufficiently small and satisfies the following Eq (4.2)

    ε=12min{αM,λ1Mc2c3,λ2Mσ,τM,c1ηnpM,k1M,c2k2v2τM,c2k3τM,(c2+c3)k4M}. (4.2)

    We divide the domain R5+D into the ten regions is follows

    D1={(C,u,p,b,A)R5+,0<C<ε},D6={(C,u,p,b,A)R5+,C>1ε},D2={(C,u,p,b,A)R5+,0<u<ε},D7={(C,u,p,b,A)R5+,u>1ε},D3={(C,u,p,b,A)R5+,0<p<ε},D8={(C,u,p,b,A)R5+,p>1ε},D4={(C,u,p,b,A)R5+,0<b<ε3},D9={(C,u,p,b,A)R5+,b>1ε3},D5={(C,u,p,b,A)R5+,0<A<εn+1},D10={(C,u,p,b,A)R5+,A>1εn+1}.

    Obviously, Θcε=R5+/Θc=D10i=1Θi. In what follows, we will prove that

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)R5+.

    We divide the proof into ten cases.

    Case 1: If (C,u,p,b,A)D1, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M1ε(λ1+v2ε+v3ε)+Mλ1ε+Mv2v3.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D1.

    Case 2: If (C,u,p,b,A)D2, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M1ε(λ2+σε)+Mλ2ε+Mσ.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D2.

    Case 3: If (C,u,p,b,A)D3, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M1ε(λ3+σε)+Mλ3ε+Mσ.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D3.

    Case 4: If (C,u,p,b,A)D4, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+Mτε2ε3+Mτε+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D4.

    Case 5: If (C,u,p,b,A)D5, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+Mαεnεn+1+Mαε+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D5.

    Case 6: If (C,u,p,b,A)D6, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+Mk1ε+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D6.

    Case 7: If (C,u,p,b,A)D7, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M1ε(c2k2v2τ)+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D7.

    Case 8: If (C,u,p,b,A)D8, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M1ε(c3k3τ)+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D8.

    Case 9: If (C,u,p,b,A)D9, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+M1ε(c2+c3)k4+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D9.

    Case 10: If (C,u,p,b,A)D10, we can derive that

    LW(c1ηnρ)Ak1C(c2k2v2τ)u(c3k3τ)p(c2+c3)k4bαunA1C(λ1+v2u+v3P)1u(λ2+σb)1p(λ3+σb)τupb+Mc1ηnρε+M.

    According to (4.2),

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)D10.

    Including the analysis from Cases 1 to 10, we can derive that

    LW(C,u,p,b,A)<0, for any (C,u,p,b,A)R5+.

    Consequently, condition (2) in Lemma 2 is satisfied. This finishes the proof.

    In this section we are going to discuss under what conditions the disease will be extinct, for convenient, we define X(t)=1tt0x(r)dr, and define another threshold parameter as follows:

    R1=(σ+k4)(λ2+v1)k4(σ+k4+ξ242),R2=λ2+v1η+ξ252.

    Theorem 4. If R1<1 and R2<1 hold, the b(t) and A(t) will die out with probability one, moreover

    limtA(t)=0,limtp(t)=λ3k3,limtb(t)=0,a.s.

    Proof. By using the Itô's formula to the equation of model (2.2), we can get

    d(σσ+k4b+u)=[λ2k4σ+k4τup+v1ck+cαnunρμAk2μ]dt+ξ2udB2(t)+σσ+k4ξ4bdB4(t).

    Integration both sides of the equation above from 0 to t, we get

    σσ+k4b(t)b(0)t+u(t)u(0)t=λ2k4σ+k4τup+v1ck+cαnunρuAk2u+ξ2tt0u(s)dB2(s)+σξ4(σ+k4)tt0b(s)dB4(s).

    By simple calculation, we can obtain

    τup=σ+k4k4(λ2+v1ck+c)σ+k4k4(αnun+ρuA+k2u)+ϕ1(t),

    where the value of ϕ1(t) is defined via the subsequent equation

    ϕ1(t)=σ1k4k4ξ2tM1(t)+σξ4k4tM2(t)σk4b(t)b(0)tσ+k4k4u(t)u(0)t.

    With the large number theorem as stated in Lemma 3 and local martingales, limtϕ1(t)=0. Similarly, we also can get

    αnun=λ2+v1ck+c(k4σ+k4τup+ρuA+k2u)+ϕ2(t),

    where ϕ2(t) is defined by

    ϕ2(t)=ξ2tM1(t)+σξ4(σ+k4)tM2(t)σσ+k4b(t)b(0)tu(t)u(0)t.

    Similarly, limtϕ2(t)=0.

    Likewise, we integrate both sides of the last two equations of the proposed model (2.2), yielding these equations

    d(p+b)=λ3k3pk4b+ξ3pdB3(t)+ξ3bdB4(t)

    and

    p(t)p(0)t+b(t)b(0)t=λ3k3pk4b+ξ3tt0p(s)dB3(t)+ξ4tt0b(s)dB4(t).

    With a simple calculation, we can get

    p=λ3k3k4k3b+ϕ3(t),

    where

    ϕ3(t)=1k3[p(t)p(0)tb(t)b(0)t+ξ3tt0p(s)dB3(s)+ξ4tt0b(s)dB4(s)].

    Clearly, limtϕ3(t)=0.

    By using the Itô's formula on the fourth equation of model (2.2), we have

    dlnb(t)=τupb(σ+k4)ξ242+ξ4tt0B4(t)σ+k4k4(λ2+v1ck+c)σ+k4k4(αnun+ρuA+k2u)+ϕ1(t)(σ+k4)ξ242+ξ4tt0B4(t)(σ+k4)(λ2+v1)k4+ϕ1(t)(σ+k4+ξ242)+ξ4tt0B4(t)=(σ+k4+ξ242)(R11)+ϕ1(t)+ξ4tt0B4(t).

    Obviously,

    limtsupξ4tt0B4(t)=0,a.s.

    Therefore when R1<1, we obtain

    limtsuplnb(t)t(σ+k4+ξ242)(R11)<0.

    That implies that,

    limtb(t)=0,a.s.

    In the same way, by applying the Itô's formula to the last equation of model (2.2), we can obtain,

    dlnnA=αnunnAηξ252+ξ5tt0B5(t)αnunηξ252+ξ5tt0B5(t)=λ2+v1ck+c(k4σ+k4τup+ρuA+k2u)+ϕ2(t)ηξ252+ξ5tt0B5(t)λ2+v1(η+ξ252)+ϕ2(t)+ξ5tt0B5(t)=(η+ξ252)(R21)+ϕ2(t)+ξ5tt0B5(t).

    Obviously,

    limtsupξ5tt0B5(t)=0,a.s.

    Therefore when R2<1, we obtain

    limtsuplnnA(t)t(η+ξ252)(R21)<0.

    It implies that,

    limtnA(t)=0,a.s.

    That is to say

    limtA(t)=0,a.s.

    With p=λ3k3k4k3b+ϕ3(t) above, we can get that

    limtp(t)=λ3k3,a.s.

    This completes the proof.

    Remark 1. Theorem 4 reveals that the extinction or not of the disease depends on the sign of R1 and R2. With Ri<1(i=1,2), both the Aβ oligomers and Aβ-x-PrPC complex incline to go extinct. That is, stochastic perturbations of the environment are beneficial to the extinction of both materials. This means that in real life, it is useful to pay attention to the physical condition of the patient and improve the internal environment of the body [33]. A more interesting result is that such random perturbations may lead to disease extinction. This provides a theoretical basis for disease cure.

    To illustrate the theoretical results obtained, we give some examples in this section. Using the Milstein's higher order method developed in [34], we present our results. Let us consider the corresponding discretizing equations,

    {Ci+1=Ci+(λ1+v2uiv3piCik1Ci)Δt+ξ1ϖ1,iCiΔt+12ξ21Ci(ϖ21,i1)Δt,ui+1=ui+(λ2τuipi+σbi+v1Cik+CiαnuniρuiAik2ui)Δt+ξ2ϖ2,iuiΔt+12ξ22ui(ϖ22,i1)Δt,pi+1=pi+(λ3τuipi+σbik3pi)Δt+ξ3ϖ3,ipiΔt+12ξ23pi(ϖ23,i1)Δt,bi+1=bi+(τuipiσbik4bi)Δt+ξ4ϖ4,ibiΔt+12ξ24bi(ϖ24,i1)Δt,Ai+1=Ai+(αuniηAi)Δt+ξ5ϖ5,iAiΔt+12ξ25Ai(ϖ25,i1)Δt.

    Where ϖj,ij=1,2,3,4,5 are the realization of five independent Gaussian random variables with distribution N(0,1) and time step Δt=0.01. Using MATLAB, numerical simulations were performed on the proposed stochastic Alzheimer's disease model (2.2) and an approximate solution of the model is obtained. In addition, it is shown that noise intensity has a significant influence. By assuming numerical values of the parameters related to their biological feasibility, we verified the extinction of the disease and the existence of a stationary distribution.

    First, we choose λ1=0.2, v1=1, v2=0.6, v3=0.4, k1=7, ξ1=0.1, k=0.3, k2=0.35, ρ=0.5, ξ2=0.25, λ3=0.5, k3=0.2, ξ3=0.2, τ=0.85, σ=0.6, η=0.8, α=0.3, n=3, ξ5=0.5, ξ4=0.1. Furthermore, we consider the initial size of population density as X(0)=(C(0),u(0),p(0),b(0),A(0))=(0.2,0.5,0.5,1.2,1). These assumptions satisfy the Theorem 3, which implies that model (2.2) has a unique stationary distribution as shown in Figure 1 and means the disease will be persistent.

    Figure 1.  The stationary distribution of the Alzheimer's disease, five small images of (a) show the changes of C, u, p, b and A number over a period of time. (b) are the number histogram of C, u, p, b and A, respectively.

    Next, based on the previous assumptions, we change λ1, v1, ξ1, k2, ξ2, λ3, ξ3, η, ξ4, ξ5 to be λ1=0.02, v1=0.08, ξ1=2.8, k2=3, ξ2=4, λ3=0.85, ξ3=5, η=0.12, ξ4=0.6 and ξ5=1.6. We can easily calculate the basic reproduction number R1=0.8556<1 and R2=0.2357<1. And according to Theorem 4 the solution of model (2.2) must obey

    limtsuplnb(t)t(σ+k4+ξ242)(R11)<0

    and

    limtsuplnnA(t)t(η+ξ252)(R21)<0.

    This means that the disease will die out in this case and the numerical simulation of Figure 2 confirms our theoretical results. Figure 2 shows that the stochastic equation (2.2) and the deterministic equation have differences in their behavior. By this, we can point out that the disease tends towards the extinction with environmental noise. The numerical simulation shows that the surrounding noise have a very large effect on the mentioned disease. That is, the environmental interference will cause the Aβ plaque and AβxPrPC complex to disappear.

    Figure 2.  The extinction of Aβ plaques and Aβ-x-PrPC complex on the stochastic model (2.2) along with its corresponding deterministic model (ξi=0,i=1,2,...,5).

    Finally, to simulate the effect of different intensities of environmental interference, we fix the parameters above except ξ4 and ξ5. We change the values of ξ4 and ξ5 in Figure 3. As the intensity of white noise increases, Aβ plaques and Aβ-x-PrPC complex will accelerate extinction.

    Figure 3.  The effects of the environmental random disturbance on Aβ plaques and Aβ-x-PrPC complex.

    During neural signaling, the concentration of Aβ is influenced by a number of stochastic factors. For example, calcium ions can regulate of Aβ levels in the interstitial fluid (ISF) by affecting the permeability of the cell membrane. We established a random Alzheimer's disease model containing Ca2+ and investigated the transmission dynamics with changing biological environment. Using the stochastic Lyapunov functions theory, the existence and positivity were proved. The extinction and the stationary distribution were also discussed, the related conditions implied that the random parameters such as the random of Ca2+ concentration will lead to disease's extinction. In contrast to the optimal control conditions proposed by Hu et al. [14], this paper directly derives more explicit and simple conditions for the extinction of Aβ plaques and AβxPrPC complex, which will form the basis in formulating novel therapeutic solutions for control strategies regarding AD pathology. In the future, the model can be further extended by adding drugs. One can also talk about the drug-target kinetics of the model by adding drugs and the influence of toxicological effects of drugs on therapeutic efficacy.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.

    This work was supported by the National Natural Science Foundation of China (Nos. 12271068, 11961024), the Group Building Scientific Innovation Project for Universities in Chongqing (No. CXQT21021), the Joint Training Base Construction Project for Graduate Students in Chongqing (No. JDLH PYJD2021016), the Innovation Project for Graduate Research in Chongqing Jiaotong University (No. 2023ST011).

    The authors declare that they have no conflicts of interest related to this article.



    [1] S. Jean-Marie, Z. Jadwiga, J. Pierre, A possible role for CSF turnover and choroid plexus in the pathogenesis of late onset Alzheimer's disease, J. Alzheimer's Dis., 30 (2012), 17–26. https://doi.org/10.3233/JAD-2012-111964 doi: 10.3233/JAD-2012-111964
    [2] R. Bai, W. Dong, Trends in mortality rates for Alzheimer's disease and other dementias over 30 years in China, Am. J. Alzheimer's Dis., 36 (2021), 1–8. https://doi.org/10.1177/15333175211044884 doi: 10.1177/15333175211044884
    [3] Alzheimer's Association Report, 2021 Alzheimer's disease facts and figures, Alzheimer's Dement., 17 (2021), 327–406. https://doi.org/10.1002/alz.12328 doi: 10.1002/alz.12328
    [4] L. Söderberg, M. Johannesson, P. Nygren, H. Laudon, F. Eriksson, G. Osswald, et al., Lecanemab, Aducanumab, and Gantenerumab–Binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's disease, Neurotherapeutics, 20 (2023), 195–206. https://doi.org/10.1007/s13311-022-01308-6 doi: 10.1007/s13311-022-01308-6
    [5] J. Cummings, P. Aisen, C. Lemere, A. Atri, M. Sabbagh, S. Salloway, Aducanumab produced a clinically meaningful benefit in association with amyloid lowering, Alz. Res. Therapy, 13 (2021), 98. https://doi.org/10.1186/s13195-021-00838-z doi: 10.1186/s13195-021-00838-z
    [6] K. Wojtunik-Kulesza, M. Rudkowska, A. Orzeł-Sajdłowska, Aducanumab-Hope or disappointment for Alzheimer's disease, Int. J. Mol. Sci., 24 (2023), 4367. https://doi.org/10.3390/ijms24054367 doi: 10.3390/ijms24054367
    [7] Y. Huang, L. Mucke, Alzheimer mechanisms and therapeutic strategies, Cell, 148 (2012), 1204–1222. https://doi.org/10.1016/j.cell.2012.02.040 doi: 10.1016/j.cell.2012.02.040
    [8] M. P. Lambert, A. K. Barlow, B. A. Chromy, W. L. Klein, Diffusible, nonfibrillar ligands derived from Aβ142 are potent central nervous system neurotoxins, Proc. Natl. Acad. Sci. USA, 95 (1998), 6448–6453. https://doi.org/10.1073/pnas.95.11.6448 doi: 10.1073/pnas.95.11.6448
    [9] M. Hoore, S. Khailaie, G. Montaseri, T. Mitra, M. Meyer-Hermann, Mathematical model shows how sleep may affect amyloid-β fibrillization, Biophys. J., 119 (2018), 862–872. https://doi.org/10.1016/j.bpj.2020.07.011 doi: 10.1016/j.bpj.2020.07.011
    [10] H. Li, H. Zhao, Mathematical model of Alzheimer's disease with prion proteins interactions and treatment, Appl. Math. Comput., 433 (2022), 127377. https://doi.org/10.1016/j.amc.2022.127377 doi: 10.1016/j.amc.2022.127377
    [11] F. Dohler, D. Sepulveda-Falla, S. Krasemann, H. Altmeppen, H. Schlüter, D. Hildebrand, et al., High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease, Brain, 137 (2014), 873–886. https://doi.org/10.1093/brain/awt375 doi: 10.1093/brain/awt375
    [12] B. Mroczko, M. Groblewska, A. Litman-Zawadzka, J. Kornhuber, P. Lewczuk, Amyloid β oligomers (AβOs) in Alzheimer's disease, J. Neural Transm., 125 (2018), 177–191. https://doi.org/10.1007/s00702-017-1820-x doi: 10.1007/s00702-017-1820-x
    [13] M. Helal, E. Hingant, L. Pujo-Menjouet, G. F. Webb, Alzheimer's disease: analysis of a mathematical model incorporating the role of prions, J. Math. Biol., 69 (2014), 1207–1235. https://doi.org/10.1007/s00285-013-0732-0 doi: 10.1007/s00285-013-0732-0
    [14] J. Hu, Q. Zhang, A. Meyer-Baese, M. Ye, Finite-time stability and optimal control of a stochastic reaction-diffusion model for Alzheimer's disease with impulse and time-varying delay, Appl. Math. Model., 102 (2022), 511–539. https://doi.org/10.1016/j.apm.2021.10.004 doi: 10.1016/j.apm.2021.10.004
    [15] B. Fang, D. Wang, M. Huang, G. Yu, H. Li, Hypothesis on the relationship between the change in intracellular pH and incidence of sporadic Alzheimer's disease or vascular dementia, Int. J. Neurosci. 120 (2010), 591–595. https://doi.org/10.3109/00207454.2010.505353 doi: 10.3109/00207454.2010.505353
    [16] A. De Mario, C. Peggion, M. L. Massimino, F. Viviani, A. Castellani, M. Giacomello, et al., The prion protein regulates glutamate-mediated Ca2+ entry and mitochondrial Ca2+ accumulation in neurons, J. Cell Sci., 130 (2017), 2736–2746. https://doi.org/10.1242/jcs.196972 doi: 10.1242/jcs.196972
    [17] H. J. Kwon, M. Y. Cha, D. Kim, D. K. Kim, M. Soh, K. Shin, et al., Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer's disease, ACS Nano, 10 (2016), 2860–2870. https://doi.org/10.1021/acsnano.5b08045 doi: 10.1021/acsnano.5b08045
    [18] A. Pannaccione, I. Piccialli, A. Secondo, R. Ciccone, P. Molinaro, F. Boscia, et al., The Na+/Ca2+exchanger in Alzheimer's disease, Cell Calcium, 87 (2020), 102190. https://doi.org/10.1016/j.ceca.2020.102190 doi: 10.1016/j.ceca.2020.102190
    [19] J. De Caluwé, G. Dupont, The progression towards Alzheimer's disease described as a bistable switch arising from the positive loop between amyloids and Ca2+, J. Theor. Biol., 331 (2013), 12–18. https://doi.org/10.1016/j.jtbi.2013.04.015 doi: 10.1016/j.jtbi.2013.04.015
    [20] B. Øksendal, Stochastic differential equations: an introduction with applications, Heidelberg: Springer Berlin, 2003. https://doi.org/10.1007/978-3-642-14394-6
    [21] M. Xin, B. Wang, Stationary distribution and extinction of a stochastic tuberculosis model, Phys. A, 545 (2020), 123741. https://doi.org/10.1016/j.physa.2019.123741 doi: 10.1016/j.physa.2019.123741
    [22] M. Liu, M. Deng, Permanence and extinction of a stochastic hybrid model for tumor growth, Appl. Math. Lett., 94 (2019), 66–72. https://doi.org/10.1016/j.aml.2019.02.016 doi: 10.1016/j.aml.2019.02.016
    [23] Y. Tan, Y. Cai, X. Wang, Z. Peng, K. Wang, R. Yao, et al., Stochastic dynamics of an SIS epidemiological model with media coverage, Math. Comput. Simul., 204 (2023), 1–27. https://doi.org/10.1016/j.matcom.2022.08.001 doi: 10.1016/j.matcom.2022.08.001
    [24] J. Hu, Q. Zhang, A. Meyer-Baese, M. Ye, Stationary distribution of a stochastic Alzheimer's disease model, Math. Methods Appl. Sci., 43 (2020), 9706–9718. https://doi.org/10.1002/mma.6642 doi: 10.1002/mma.6642
    [25] T. Matsubara, K. Satoh, T. Homma, T. Nakagaki, N. Yamaguchi, R. Atarashi, et al., Prion protein interacts with the metabotropic glutamate receptor 1 and regulates the organization of Ca2+ signaling, Biochem. Biophys. Res. Commun., 525 (2020), 447–454. https://doi.org/10.1016/j.bbrc.2020.02.102 doi: 10.1016/j.bbrc.2020.02.102
    [26] J. Latulippe, D. Lotito, D. Murby, A mathematical model for the effects of amyloid beta on intracellular calcium, PLoS One, 13 (2018), 1–27. https://doi.org/10.1371/journal.pone.0202503 doi: 10.1371/journal.pone.0202503
    [27] A. Din, T. Khan, Y. Li, H. Tahir, A. Khan, W. A. Khan, Mathematical analysis of dengue stochastic epidemic model, Results Phys., 20 (2021), 103719. https://doi.org/10.1016/j.rinp.2020.103719 doi: 10.1016/j.rinp.2020.103719
    [28] W. Wang, A. Zazoua, Analysis of mathematical model of prostate cancer with androgen deprivation therapy, Commun. Nonlinear Sci. Numer. Simul., 66 (2019), 41–60. https://doi.org/10.1016/j.cnsns.2018.06.004 doi: 10.1016/j.cnsns.2018.06.004
    [29] Y. Wang, D. Jiang, Stationary distribution and extinction of a stochastic viral infection model, Discrete Dyn. Nat. Soc., 2017 (2017), 6027509. https://doi.org/10.1155/2017/6027509 doi: 10.1155/2017/6027509
    [30] R. Khasminskii, Stochastic stability of differential equations, Heidelberg: Springer Berlin, 2012. https://doi.org/10.1007/978-3-642-23280-0
    [31] X. Mao, C. Yuan, J. Zou, Stochastic differential delay equations of population dynamics, J. Math. Anal. Appl., 304 (2005), 296–320. https://doi.org/10.1016/j.jmaa.2004.09.027 doi: 10.1016/j.jmaa.2004.09.027
    [32] G. Lan, Z. Lin, C. Wei, S. Zhang, A stochastic SIRS epidemic model with non-monotone incidence rate under regime-switching, J. Franklin Inst., 16 (2019), 9844–9866. https://doi.org/10.1016/j.jfranklin.2019.09.009 doi: 10.1016/j.jfranklin.2019.09.009
    [33] J. Olazarán, B. Reisberg, L. Clare, I. Cruz, J. Peña-Casanova, T. del Ser, et al., Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy, Dement. Geriatr. Cogn. Disord., 30 (2010), 161–178. https://doi.org/10.1159/000316119 doi: 10.1159/000316119
    [34] D. J. Higham, An algorithmic introduction to numerical simulation of stochastic differential equations, SIAM Rev., 43 (2001), 525–546. https://doi.org/10.1137/S0036144500378302 doi: 10.1137/S0036144500378302
  • This article has been cited by:

    1. Mitali Maji, Subhas Khajanchi, Mathematical models on Alzheimer's Disease and its treatment: A review, 2025, 15710645, 10.1016/j.plrev.2025.01.004
  • Reader Comments
  • © 2023 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(1658) PDF downloads(110) Cited by(1)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog